ArticleMolecular biology reports2026
ATP5F1B promotes breast cancer progression through ERK associated metabolic reprogramming.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo systematically evaluate the prognostic significance of mitochondrial ATP synthase subunits in breast cancer and to investigate the clinical relevance, biological function, and metabolic role of ATP5F1B in breast cancer progression.
methodsPublicly available breast cancer transcriptomic profiles with matched clinical annotations were analyzed in a family-level screen of mitochondrial ATP synthase subunits. ATP5F1B was prioritized and was evaluated by loss- and gain-of-function assays in AU565 and HCC1428 cells. Differential expression and functional enrichment analyses were performed, and metabolic activity was assessed by extracellular acidification rate. Key genes and proteins were validated by qRT-PCR and Western blotting.
resultsATP5F1B was upregulated in tumor tissues and emerged as the only screened F1 subunit consistently associated with survival. High ATP5F1B expression was linked to poorer overall survival, disease-specific survival, and progression-free interval, and correlated with clinicopathologic features, including age, estrogen receptor status, and PAM50 subtypes, with enrichment in Luminal B and HER2-enriched tumors. ATP5F1B knockdown reduced proliferation and clonogenic growth, whereas ATP5F1B overexpression enhanced cell growth and was accompanied by decreased BAX and increased BCL-2. Transcriptomic analyses identified ATP5F1B-associated gene expression programs with significant GO/KEGG enrichment. Metabolically, ATP5F1B depletion reduced glycolytic activity and downregulated HK2, PKM2, LDHA, CHPT1, LPCAT1, and ERK-related transcriptional expression.
conclusionsATP5F1B is associated with poor prognosis and promotes breast cancer cell growth, potentially through metabolic regulation.
Indexed as
Identifiers
42397624What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.